Binimetinib

Description: Binimetinib / MEK162 / ARRY-162 is an oral highly selective MEK inhibitor ( IC50/MEK1/2, 12 nM in a cell-free assay). MEK162 is the first targeted therapy to show activity in patients with NRAS -mutated melanoma and might offer a new option for a cancer with few effective treatments and in Phase 3.

• Catalog: OFC606143899
• CAS: 606143-89-9
• Category: Fluorinated APIs
• Synonyms: MEK-162
• Purity: >98%

• IUPAC Name: 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
• InChI: InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
• InChI Key: ACWZRVQXLIRSDF-UHFFFAOYSA-N
• Isomeric SMILES: CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
• EC Number: 639-995-7

• Molecular Formula: C17H15BrF2N4O3
• Molecular Weight: 441.23
• Appearance: White to off-white solid powder

• XLogP3-AA: 3.1
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 7
• Rotatable Bond Count: 6
• Exact Mass: 440.02956 g/mol
• Monoisotopic Mass: 440.02956 g/mol
• Topological Polar Surface Area: 88.4Ų
• Heavy Atom Count: 27
• Formal Charge: 0
• Complexity: 521